PPD increases focus on vaccines and biologics

By Nick Taylor

- Last updated on GMT

Related tags Immune system Vaccine Biotechnology

PPD has added capabilities at the facility acquired from Merck & Co and improved integration of other sites to create its Vaccines & Biologics Center of Excellence, a single provider of multiple laboratory services.

Enhancing its services is intended to strengthen PPD’s position in a growth sector. Christine Dingivan, chief medical officer at PPD, believes it is the only contract research organisation (CRO) that can offer a “comprehensive range of testing services for vaccine and other biologics​”.

Dingivan explained to Outsourcing-Pharma that PPD has worked to integrate its sites “to create a network of labs with services tailored to support vaccines and biologics programmes​”. This covers vaccine testing, bioanalytical, good manufacturing practice (GMP) and central lab capabilities.

Furthermore, PPD has launched new capabilities at the vaccine testing site in Wayne, Pennsylvania, US which it acquired from Merck & Co in January 2009. These services include an expanded range of vaccine assays and enhanced cell culture and GMP capabilities.

Integrating these offerings as the Vaccines & Biologics Center of Excellence will allow PPD to provide more cost efficient services, reduce lab transfers, simplify logistics and streamline project management, according to Dingivan.

In addition, the project is intended to improve data integration. Dingivan explained that PPD can provide consistent sample management and data integration interface between the clinical, central laboratory and vaccine sites.

Further expansion

PPD has the industry’s largest collection of commercial vaccine assays, according to Dingivan, and can “provide clientswith an all-inclusive menu of assay development services for vaccine clinical trials​”.

Dingivan added that PPD will continue to invest and expand this portfolio. In particular PPD is looking to expand in oncology and infectious diseases, according to Dingivan, because of increased vaccine and monoclonal antibody use in these fields.

We will also continue to invest in our network of global central lab, bioanalytical and cGMP laboratory facilities with a particular focus on the Asia Pacific region​”, added Dingivan.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Products

View more

Webinars